<VariationArchive VariationID="2095106" VariationName="NM_000276.4(OCRL):c.1822dup (p.Ser608fs)" VariationType="Duplication" Accession="VCV002095106" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-29" DateCreated="2023-02-08" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2156890" VariationID="2095106">
      <GeneList>
        <Gene Symbol="OCRL" FullName="OCRL inositol polyphosphate-5-phosphatase" GeneID="4952" HGNC_ID="HGNC:8108" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xq26.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="129540259" stop="129592556" display_start="129540259" display_stop="129592556" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="128674251" stop="128726532" display_start="128674251" display_stop="128726532" Strand="+" />
          </Location>
          <OMIM>300535</OMIM>
          <Haploinsufficiency last_evaluated="2021-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=OCRL">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=OCRL">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000276.4(OCRL):c.1822dup (p.Ser608fs)</Name>
      <CanonicalSPDI>NC_000023.11:129576004:A:AA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>Xq26.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="129576004" stop="129576005" display_start="129576004" display_stop="129576005" variantLength="1" positionVCF="129576004" referenceAlleleVCF="C" alternateAlleleVCF="CA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="128709981" stop="128709982" display_start="128709981" display_stop="128709982" variantLength="1" positionVCF="128709981" referenceAlleleVCF="C" alternateAlleleVCF="CA" />
      </Location>
      <ProteinChange>S608fs</ProteinChange>
      <ProteinChange>S609fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.128709982dup" Assembly="GRCh37">
            <Expression>NC_000023.10:g.128709982dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001318784.2" sequenceAccession="NM_001318784" sequenceVersion="2" change="c.1825dup">
            <Expression>NM_001318784.2:c.1825dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001305713.1" sequenceAccession="NP_001305713" sequenceVersion="1" change="p.Ser609fs">
            <Expression>NP_001305713.1:p.Ser609fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001587.4" sequenceAccession="NM_001587" sequenceVersion="4" change="c.1822dup">
            <Expression>NM_001587.4:c.1822dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001578.2" sequenceAccession="NP_001578" sequenceVersion="2" change="p.Ser608fs">
            <Expression>NP_001578.2:p.Ser608fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.129576005dup" Assembly="GRCh38">
            <Expression>NC_000023.11:g.129576005dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008638.1" sequenceAccession="NG_008638" sequenceVersion="1" change="g.40731dup">
            <Expression>NG_008638.1:g.40731dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000276.4" sequenceAccession="NM_000276" sequenceVersion="4" change="c.1822dup" MANESelect="true">
            <Expression>NM_000276.4:c.1822dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000267.2" sequenceAccession="NP_000267" sequenceVersion="2" change="p.Ser608fs">
            <Expression>NP_000267.2:p.Ser608fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000276.4(OCRL):c.1822dup (p.Ser608fs) AND Lowe syndrome" Accession="RCV003025651" Version="2">
        <ClassifiedConditionList TraitSetID="3031">
          <ClassifiedCondition DB="MedGen" ID="C0028860">Lowe syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-06-08" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-06-08" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-08" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">19390221</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21031565</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22381590</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3031" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2569" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Oculocerebrorenal Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Lowe oculocerebrorenal syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Lowe syndrome</ElementValue>
                <XRef ID="Lowe+oculocerebrorenal+syndrome/4314" DB="Genetic Alliance" />
                <XRef ID="79385002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Phosphatidylinositol 4,5-bisphosphate 5-phosphatase deficiency</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">OCRL</ElementValue>
                <XRef Type="MIM" ID="309000" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">OCRL1</ElementValue>
                <XRef Type="MIM" ID="309000" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Lowe syndrome (oculocerebrorenal syndrome) is characterized by involvement of the eyes, central nervous system, and kidneys. Dense congenital cataracts are found in all affected boys and infantile glaucoma in approximately 50%. All boys have impaired vision; corrected acuity is rarely better than 20/100. Generalized hypotonia is noted at birth and is of central (brain) origin. Deep tendon reflexes are usually absent. Hypotonia may slowly improve with age, but normal motor tone and strength are never achieved. Motor milestones are delayed. Almost all affected males have some degree of intellectual disability; 10%-25% function in the low-normal or borderline range, approximately 25% in the mild-to-moderate range, and 50%-65% in the severe-to-profound range of intellectual disability. Affected males have varying degrees of proximal renal tubular dysfunction of the Fanconi type, including low molecular-weight (LMW) proteinuria, aminoaciduria, bicarbonate wasting and renal tubular acidosis, phosphaturia with hypophosphatemia and renal rickets, hypercalciuria, sodium and potassium wasting, and polyuria. The features of symptomatic Fanconi syndrome do not usually become manifest until after the first few months of life, except for LMW proteinuria. Glomerulosclerosis associated with chronic tubular injury usually results in slowly progressive chronic renal failure and end-stage renal disease between the second and fourth decades of life.</Attribute>
                <XRef ID="NBK1480" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3295" />
                <XRef ID="3295" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301653</ID>
                <ID Source="BookShelf">NBK1480</ID>
              </Citation>
              <XRef ID="534" DB="Orphanet" />
              <XRef ID="C0028860" DB="MedGen" />
              <XRef ID="MONDO:0010645" DB="MONDO" />
              <XRef Type="MIM" ID="309000" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5996905" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="15786992|MedGen:C0028860" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003309771" DateUpdated="2024-02-20" DateCreated="2023-02-07" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-08">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">19390221</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21031565</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22381590</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with OCRL-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Ser608Lysfs*11) in the OCRL gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in OCRL are known to be pathogenic (PMID: 19390221, 21031565, 22381590).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="OCRL" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.128709981_128709982insA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0028860" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14200279</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5996905" TraitType="Disease" MappingType="XRef" MappingValue="C0028860" MappingRef="MedGen">
        <MedGen CUI="C0028860" Name="Lowe syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

